^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | retlirafusp alfa (SHR-1701) (PD-L1 inhibitor, TGF-β R2 kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
Published date:
10/25/2022
Excerpt:
In the clinical-expansion part, SHR-1701 showed the most favorable efficacy in the gastric cancer cohort, with an ORR of 20.0% (7/35; 95% CI, 8.4-36.9) and a 12-month overall survival rate of 54.5% (95% CI, 29.5 73.9)...Generally, patients with PD-L1 CPS ≥1 or pSMAD2 histochemical score ≥235 had numerically higher ORR...SHR-1701 showed an acceptable safety profile and encouraging antitumor activity in pretreated advanced solid tumors, especially in gastric cancer, establishing the foundation for further exploration.
DOI:
10.1186/s12916-022-02605-9
Trial ID:
Source:
Title:
1375P - SHR-1701, a novel bifunctional anti-PD-L1/TGF-ßRII agent, for pretreated recurrent/refractory (r/r) gastric cancer (GC): Data from a first-in-human phase I study
Published date:
09/13/2021
Excerpt:
Exploratory analyses showed a trend towards favourable responses for pts with a PD-L1 CPS ≥5 (Table)...ORR, n (%; 95% CI), DCR, n (%; 95% CI), and CBR, n (%; 95% CI) were found to be 4 (44.4%; 13.7-78.8), 4 (44.4%; 13.7-78.8), and 4 (44.4%; 13.7-78.8) respectively...SHR-1701 showed encouraging antitumor activity and manageable safety profile in pretreated r/r GC pts.
Trial ID:
